MOLN.SW SIX
Molecular Partners AG
1W: +3.4%
1M: -4.9%
3M: +3.1%
YTD: -6.2%
1Y: +14.4%
3Y: -35.2%
5Y: -81.6%
CHF 3.33 ($4.02)
-0.01 (-0.30%)
Weekly Expected Move ±6.3%
CHF 3
CHF 3
CHF 3
CHF 4
CHF 4
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
#15
of 20
Biotechnology
Technical Signal Map
6 Bullish
1 Neutral
6 Bearish
MOLN.SW
$120M
Molecular Partners AG
LEAN BEAR
-26
BANB.SW
$6.8B
Bachem Holding AG
BULLISH
+58
6160.HK
$300B
BeOne Medicines AG
BULLISH
+40
688235.SS
$276B
BeOne Medicines Ltd. Class A
BULLISH
+36
LONN.SW
$48B
Lonza Group AG
BULLISH
+34
BSLN.SW
$960M
Basilea Pharmaceutica AG
BULLISH
+31
KURN.SW
$950M
Kuros Biosciences AG
LEAN BULL
+27
CRSP
$5.3B
CRISPR Therapeutics AG
NEUTRAL
+8
IDIA.SW
$1.4B
Idorsia Ltd
BEARISH
-75
PHVS
$2.2B
Pharvaris N.V.
BEARISH
-84
0RQE.IL
$1.2B
Idorsia Ltd.
BEARISH
-91
MLTX
$960M
MoonLake Immunotherapeutics
BEARISH
-91
OCS
$500M
Oculis Holding AG
BEARISH
-91
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| MOLN.SW Molecular Partners AG | $120M | -2.4 | -62.0 | 642.5 | — | -100.0 | 2 | LEAN BEAR | 14.4 |
| BANB.SW Bachem Holding AG | $6.8B | 39.8 | 20.6 | 17.3 | 15.4 | 24.4 | 6 | BULLISH | 20.1 |
| 6160.HK BeOne Medicines AG | $300B | 59.5 | 14.6 | 57.1 | 13.9 | 34.2 | 8 | BULLISH | 10.8 |
| 688235.SS BeOne Medicines Ltd. Class A | $276B | 26.3 | 14.7 | 57.4 | 13.9 | 31.9 | 8 | BULLISH | 17.7 |
| LONN.SW Lonza Group AG | $48B | -367.3 | 7.1 | 17.8 | 17.5 | 3.1 | 6 | BULLISH | -1.3 |
| BSLN.SW Basilea Pharmaceutica AG | $960M | 15.7 | 130.7 | 170.3 | 23.5 | 33.6 | 8 | BULLISH | 43.0 |
| KURN.SW Kuros Biosciences AG | $950M | 102.9 | 1.5 | 6.0 | 4.8 | 237.0 | 4 | LEAN BULL | -28.0 |
| CRSP CRISPR Therapeutics AG | $5.3B | -11.6 | -26.1 | -253.2 | -895.3 | -62.7 | 2 | NEUTRAL | -16.2 |
| IDIA.SW Idorsia Ltd | $1.4B | -3.4 | 27.1 | -526.5 | -201.9 | -8.0 | 1 | BEARISH | 61.0 |
| PHVS Pharvaris N.V. | $2.2B | -10.3 | -70.7 | 860.9 | — | — | 4 | BEARISH | 29.6 |
| 0RQE.IL Idorsia Ltd. | $1.2B | — | — | — | — | — | — | BEARISH | — |
| MLTX MoonLake Immunotherapeutics | $960M | -3.0 | -67.4 | 2902.7 | — | — | 1 | BEARISH | 61.6 |
| OCS Oculis Holding AG | $500M | -5.2 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -49.8 |
| MOLN.SW Molecular Partners AG | $120M | -2.4 | -62.0 | 642.5 | — | -100.0 | 2 | LEAN BEAR | 14.4 |
| BANB.SW Bachem Holding AG | $6.8B | 39.8 | 20.6 | 17.3 | 15.4 | 24.4 | 6 | BULLISH | 20.1 |
| 6160.HK BeOne Medicines AG | $300B | 59.5 | 14.6 | 57.1 | 13.9 | 34.2 | 8 | BULLISH | 10.8 |
| 688235.SS BeOne Medicines Ltd. Class A | $276B | 26.3 | 14.7 | 57.4 | 13.9 | 31.9 | 8 | BULLISH | 17.7 |
| LONN.SW Lonza Group AG | $48B | -367.3 | 7.1 | 17.8 | 17.5 | 3.1 | 6 | BULLISH | -1.3 |
| BSLN.SW Basilea Pharmaceutica AG | $960M | 15.7 | 130.7 | 170.3 | 23.5 | 33.6 | 8 | BULLISH | 43.0 |
| KURN.SW Kuros Biosciences AG | $950M | 102.9 | 1.5 | 6.0 | 4.8 | 237.0 | 4 | LEAN BULL | -28.0 |
| CRSP CRISPR Therapeutics AG | $5.3B | -11.6 | -26.1 | -253.2 | -895.3 | -62.7 | 2 | NEUTRAL | -16.2 |
| IDIA.SW Idorsia Ltd | $1.4B | -3.4 | 27.1 | -526.5 | -201.9 | -8.0 | 1 | BEARISH | 61.0 |
| PHVS Pharvaris N.V. | $2.2B | -10.3 | -70.7 | 860.9 | — | — | 4 | BEARISH | 29.6 |
| 0RQE.IL Idorsia Ltd. | $1.2B | — | — | — | — | — | — | BEARISH | — |
| MLTX MoonLake Immunotherapeutics | $960M | -3.0 | -67.4 | 2902.7 | — | — | 1 | BEARISH | 61.6 |
| OCS Oculis Holding AG | $500M | -5.2 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -49.8 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
MOLN.SW vs Benchmarks
ROIC
Revenue Growth
P/E Ratio
ROE
Piotroski F